Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Ann Nutr Metab. 2013;63(1-2):1-9. doi: 10.1159/000349922. Epub 2013 Jul 5.
We are aware of no study that has indicated the effects of daily consumption of multispecies probiotic supplements on metabolic profiles, high-sensitivity C-reactive protein (hs-CRP), and oxidative stress in diabetic patients.
This study was designed to determine the effects of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in diabetic patients.
This randomized double-blind placebo-controlled clinical trial was performed on 54 diabetic patients aged 35-70 years. Subjects were randomly assigned to take either a multispecies probiotic supplement (n = 27) or placebo (n = 27) for 8 weeks. The multispecies probiotic supplement consisted of 7 viable and freeze-dried strains: Lactobacillus acidophilus (2 × 10(9) CFU), L. casei (7 × 10(9) CFU), L. rhamnosus (1.5 × 10(9) CFU), L. bulgaricus (2 × 10(8) CFU), Bifidobacterium breve (2 × 10(10) CFU), B. longum (7 × 10(9) CFU), Streptococcus thermophilus (1.5 × 10(9) CFU), and 100 mg fructo-oligosaccharide. Fasting blood samples were taken at baseline and after intervention to measure metabolic profiles, hs-CRP, and biomarkers of oxidative stress including plasma total antioxidant capacity and total glutathione (GSH).
Between-group comparisons of fasting plasma glucose (FPG) revealed that consumption of probiotic supplements prevented a rise in FPG (+28.8 ± 8.5 for placebo vs. +1.6 ± 6 mg/dl for probiotic group, p = 0.01). Although a significant within-group increase in serum insulin and low-density lipoprotein cholesterol levels was found in both the probiotic group and the placebo group, the changes were similar between the two groups. We observed a significant increase in HOMA-IR (homeostasis model of assessment-insulin resistance) in both the probiotic group (p = 0.02) and the placebo group (p = 0.001); however, the increase in the placebo group was significantly higher than that in the probiotic group (+2.38 vs. +0.78, p = 0.03). Mean changes in serum hs-CRP were significantly different between the two groups (-777.57 for the probiotic group vs. +878.72 ng/ml for the placebo group, p = 0.02). Probiotic supplementation led to a significant increase in plasma GSH levels compared to placebo (240.63 vs. -33.46 µmol/l, p = 0.03).
In conclusion, multispecies probiotic supplementation, compared with placebo, for 8 weeks in diabetic patients prevented a rise in FPG and resulted in a decrease in serum hs-CRP and an increase in plasma total GSH.
我们没有发现任何研究表明每日摄入多种益生菌补充剂对糖尿病患者的代谢谱、高敏 C 反应蛋白（hs-CRP）和氧化应激有影响。
本研究旨在确定多种益生菌补充剂对糖尿病患者代谢谱、hs-CRP 和氧化应激的影响。
这是一项随机、双盲、安慰剂对照的临床试验，共纳入 54 名年龄在 35-70 岁的糖尿病患者。受试者被随机分为两组，分别服用多种益生菌补充剂（n=27）或安慰剂（n=27），疗程为 8 周。多种益生菌补充剂由 7 种活菌和冻干菌株组成：嗜酸乳杆菌（2×10(9)CFU）、干酪乳杆菌（7×10(9)CFU）、鼠李糖乳杆菌（1.5×10(9)CFU）、保加利亚乳杆菌（2×10(8)CFU）、短双歧杆菌（2×10(10)CFU）、长双歧杆菌（7×10(9)CFU）、嗜热链球菌（1.5×10(9)CFU）和 100mg 果糖低聚糖。在基线和干预后采集空腹血样，以测量代谢谱、hs-CRP 和氧化应激的生物标志物，包括血浆总抗氧化能力和总谷胱甘肽（GSH）。
两组间空腹血糖（FPG）的比较显示，益生菌补充剂的摄入可防止 FPG 升高（安慰剂组为+28.8±8.5mg/dl，益生菌组为+1.6±6mg/dl，p=0.01）。虽然益生菌组和安慰剂组的血清胰岛素和低密度脂蛋白胆固醇水平均有显著的组内升高，但两组间的变化相似。我们观察到两组的 HOMA-IR（评估胰岛素抵抗的稳态模型）均有显著升高（益生菌组 p=0.02，安慰剂组 p=0.001）；然而，安慰剂组的升高幅度明显高于益生菌组（+2.38 对+0.78，p=0.03）。两组间血清 hs-CRP 的平均变化有显著差异（益生菌组为-777.57ng/ml，安慰剂组为+878.72ng/ml，p=0.02）。与安慰剂相比，益生菌补充剂可显著增加血浆 GSH 水平（240.63 对-33.46µmol/l，p=0.03）。
总之，与安慰剂相比，糖尿病患者连续 8 周补充多种益生菌可防止 FPG 升高，并降低血清 hs-CRP 水平，增加血浆总 GSH 水平。
